WO1998036737A1 - Procede de granulation par voie humide - Google Patents
Procede de granulation par voie humide Download PDFInfo
- Publication number
- WO1998036737A1 WO1998036737A1 PCT/US1997/002830 US9702830W WO9836737A1 WO 1998036737 A1 WO1998036737 A1 WO 1998036737A1 US 9702830 W US9702830 W US 9702830W WO 9836737 A1 WO9836737 A1 WO 9836737A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mixture
- granules
- granulating fluid
- granulating
- group
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 56
- 239000000203 mixture Substances 0.000 claims abstract description 74
- 239000008187 granular material Substances 0.000 claims abstract description 69
- 239000012530 fluid Substances 0.000 claims abstract description 44
- 239000004480 active ingredient Substances 0.000 claims abstract description 26
- 238000001035 drying Methods 0.000 claims abstract description 15
- 238000010438 heat treatment Methods 0.000 claims abstract description 11
- 239000002245 particle Substances 0.000 claims abstract description 10
- 239000004615 ingredient Substances 0.000 claims description 27
- 239000011230 binding agent Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 235000000346 sugar Nutrition 0.000 claims description 14
- -1 gums Substances 0.000 claims description 13
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 12
- 229940069428 antacid Drugs 0.000 claims description 11
- 239000003159 antacid agent Substances 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 230000001458 anti-acid effect Effects 0.000 claims description 6
- 239000003086 colorant Substances 0.000 claims description 6
- 150000005846 sugar alcohols Chemical class 0.000 claims description 5
- 229920002472 Starch Chemical class 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 230000001387 anti-histamine Effects 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- ZREIPSZUJIFJNP-UHFFFAOYSA-K bismuth subsalicylate Chemical compound C1=CC=C2O[Bi](O)OC(=O)C2=C1 ZREIPSZUJIFJNP-UHFFFAOYSA-K 0.000 claims description 2
- 229960000782 bismuth subsalicylate Drugs 0.000 claims description 2
- 239000001913 cellulose Chemical class 0.000 claims description 2
- 229920002678 cellulose Chemical class 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 239000000850 decongestant Substances 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000008202 granule composition Substances 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000008141 laxative Substances 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229910000000 metal hydroxide Inorganic materials 0.000 claims description 2
- 229910044991 metal oxide Inorganic materials 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 230000002475 laxative effect Effects 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 24
- 238000002156 mixing Methods 0.000 description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 8
- 229930195725 Mannitol Natural products 0.000 description 8
- 239000000594 mannitol Substances 0.000 description 8
- 235000010355 mannitol Nutrition 0.000 description 8
- 239000000969 carrier Substances 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 239000000825 pharmaceutical preparation Substances 0.000 description 7
- 229940127557 pharmaceutical product Drugs 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000003296 saliva Anatomy 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000003337 fertilizer Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000575 pesticide Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000011194 food seasoning agent Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 2
- UTUUIUQHGDRVPU-UHFFFAOYSA-K aluminum;2-aminoacetate;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Al+3].NCC([O-])=O UTUUIUQHGDRVPU-UHFFFAOYSA-K 0.000 description 2
- SEIGJEJVIMIXIU-UHFFFAOYSA-J aluminum;sodium;carbonate;dihydroxide Chemical compound [Na+].O[Al+]O.[O-]C([O-])=O SEIGJEJVIMIXIU-UHFFFAOYSA-J 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- PPQREHKVAOVYBT-UHFFFAOYSA-H dialuminum;tricarbonate Chemical compound [Al+3].[Al+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O PPQREHKVAOVYBT-UHFFFAOYSA-H 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 229940015828 dihydroxyaluminum sodium carbonate Drugs 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000004898 kneading Methods 0.000 description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 2
- 229940004916 magnesium glycinate Drugs 0.000 description 2
- 239000000347 magnesium hydroxide Substances 0.000 description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 238000009827 uniform distribution Methods 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- HZVVJJIYJKGMFL-UHFFFAOYSA-N almasilate Chemical compound O.[Mg+2].[Al+3].[Al+3].O[Si](O)=O.O[Si](O)=O HZVVJJIYJKGMFL-UHFFFAOYSA-N 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940118662 aluminum carbonate Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- MPRVXUYAJZZBHG-UHFFFAOYSA-K dicarbonoperoxoyloxyalumanyl hydroxy carbonate Chemical compound [Al+3].OOC([O-])=O.OOC([O-])=O.OOC([O-])=O MPRVXUYAJZZBHG-UHFFFAOYSA-K 0.000 description 1
- 229940015826 dihydroxyaluminum aminoacetate Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 235000012171 hot beverage Nutrition 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- AACACXATQSKRQG-UHFFFAOYSA-L magnesium;2-aminoacetate Chemical compound [Mg+2].NCC([O-])=O.NCC([O-])=O AACACXATQSKRQG-UHFFFAOYSA-L 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000009828 non-uniform distribution Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Definitions
- the present invention relates to a method of preparing granules comprising an active ingredient and a carrier.
- the present method is suitable for preparing granule compositions.
- Granulating techniques are widely used in various industries, for example, in the manufacture of pharmaceutical products, food products, and washing and cleaning agents.
- a starting material comprises a mixture of particles of varying sizes, or small particles (such as powder)
- these materials are typically granulated to facilitate subsequent handling in an industrial process.
- a tablet is a typical product formed by compressing granules into a predetermined shape.
- Granule properties play an important role in the overall dissolution and/or disintegration property of a tablet formed from the granules.
- the dissolution and/or disintegration property of a tablet can be of critical importance in, e.g., a pharmaceutical product.
- wet granulating methods
- dry granulating methods
- ingredients e.g., active ingredients, carriers, flavors, coloring agents, and the like
- wet granulation method is widely used and usually produces the most satisfactory results in pharmaceutical products.
- wet granulating methods known in the art for preparing granules include: mixing or blending ingredients; treating the mixture with an amount of solution comprising, for example, binding agents, to obtain a mass which is forced through a screen having openings of a predetermined size; drying on trays, in drying machines, and the like; and re-grinding and re-screening to obtain granules having suitable size such as those used for compression into tablets.
- known wet granulating methods may not be suitable for some medicinal agents which are sensitive to moisture.
- Medical agents and granulating mass used for known wet granulating methods may also be sensitive to exposure to high temperature even over a short time and/or exposure to lower temperature for a long time at the drying step, when granulating fluids are removed. Extended granule drying time is also costly, even if the resulting quality of granules is acceptable.
- the known wet granulating methods can produce undesirably hard granules.
- the hardness of a granule may be caused by using excessive levels of granulating fluids and/or excessive levels of binding agent and/or over mixing (e.g., for an extended period of time) of the components, and/or slow evaporation of any excess granulating fluid from the final products. If the granulating fluid is allowed to evaporate during storage, the granules may become undesirably hard. Consequently, tablets comprising such hard granules may also be undesirably hard. Such hardness can result in poor dissolution and/or disintegration of the tablet when contacted with saliva or water in the mouth.
- the present invention is directed to a method for making granules comprising the steps of: (a) applying a granulating fluid onto a mixture of an active ingredient and a carrier; (b) heating the mixture of step (a) in an air-tight container; and (c) drying the mixture of step (b); wherein the resulting mixture is in the form of a granule having an average particle size of from about 150 microns to about 850 microns and comprising no more than about 1.5% of the granulating fluid.
- a method satisfies the need for a wet granulating method which provides granules having improved dissolving and/or disintegrating properties when contacted with water.
- the granules obtained by the method of the present invention may further be tabletted to provide a tablet which is smooth, soft and chewable.
- the present invention is further directed to a composition comprising the granules of the present invention.
- Such a composition satisfies the need for, e.g., a tablet which is readily chewable and/or readily dissolves and/or disintegrates in one's mouth.
- the present invention relates to a method of making granules comprising:
- the resulting mixture of the present invention is in the form of a granule having an average particle size of from about 150 microns to about 850 microns and comprising no more than about 1.5% of the granulating fluid.
- the granulating method of the present invention can be used for a variety of products in different industrial areas wherein conventional wet granulating methods have been useful.
- Example products include pharmaceuticals; food, animal feed, seasoning, and beverage preparations; cleaning powders; fertilizers; pesticides; and cosmetics.
- the method of the present invention is particularly useful for granules for use in pharmaceutical products which are designed to readily dissolve and/or disintegrate upon contact with water or saliva.
- the method of the present invention is particularly useful for granules for pharmaceutical products which are subjected to tabletting.
- the first step (“step (a)"), of the present invention comprises applying a granulating fluid onto a mixture of an active ingredient and a carrier.
- the active ingredient and the carrier useful herein may be in solid or liquid form; preferably one or both are in a solid form.
- a more uniform mixture of the active ingredient and the carrier can be obtained by pre-mixing these components prior to applying the granulating fluid. Such pre-mixing of these components prior to applying the granulating fluid will result in a more uniform distribution of the active ingredient and carrier in the subsequently formed mixture.
- Any equipment which is generally used for mixing or blending ingredients such as powders are acceptable for mixing the ingredients so long as it provides generally uniform mixing, yet produce minimal dust generation.
- Equipment useful in the present method include planetary mixer, sigma mixer, mass mixer, Hobart mixer, ribbon blender, V-blender, processall mixer, and the like; preferably the planetary mixer.
- the equipment comprises a spraying system.
- the conditions for mixing ingredients and the pre-mixing, if needed, can be selected depending on the property of ingredients which are mixed.
- Active Ingredient refers to the material intended to be delivered to (e.g. ingested by) the user, via the medium of the granules of the present invention.
- the active ingredient may be any compound, preferably solid and not heat- sensitive, and thus stable under the below mentioned process conditions.
- suitable active ingredients include pharmaceuticals and health supplements, main components of food, animal feed, seasoning, and beverage preparations, surfactants for cleaning powders and effervescent tablets, fertilizing agents for fertilizers, bioactive ingredients for pesticides, and pigments for cosmetics.
- Example pharmaceuticals and health supplements which can be used as active ingredients include antacids, analgesics, anti-histamines, decongestants, herb powders, laxatives, vitamins, minerals, and mixtures thereof.
- the method of the present invention is particularly useful for making granules or tablets comprising an antacid, as antacids are generally stable to heat.
- Antacids which can be used in the present invention include those selected from the group consisting of a metal carbonate compound, a metal hydroxide compound, a metal oxide compound, a bismuth subsalicylate, and mixtures thereof.
- Nonlimiting examples of the antacids include, for example, aluminum carbonate, calcium carbonate, magnesium carbonate, aluminum hydroxy- carbonate, dihydroxy aluminum sodium carbonate, aluminum hydroxide, magnesium hydroxide, aluminum phosphate, calcium phosphate, aluminum magnesium glycinate, magnesium glycinate, dihydroxy aluminum amino acetate, dihydroxy aluminum aminoacetic acid, aluminum magnesium hydrated sulfate, magnesium aluminate, magnesium oxide, magnesium alumino silicate, magnesium trisilicate, sucralfates, and mixtures thereof.
- Preferred antacids are selected from the group consisting of calcium carbonate, dihydroxy aluminum sodium carbonate, aluminum hydroxide, magnesium hydroxide, and mixtures thereof; more preferably calcium carbonate.
- the resulting mixture of step (a) comprises an effective amount of an antacid, preferably from about 20% to about 95%, more preferably from about 35% to about 70%, more preferably still from about 40% to about 60% by weight of the mixture of the active ingredient and the carrier.
- Carrier preferably from about 20% to about 95%, more preferably from about 35% to about 70%, more preferably still from about 40% to about 60% by weight of the mixture of the active ingredient and the carrier.
- Carriers useful in the present method can be any compound which are not heat-sensitive, not moisture-sensitive, and useful for conventional wet granulating methods.
- the carrier is selected depending upon the compatibility with the active ingredient, and the desired characteristic of the product. It is recognized that some carriers may also have properties as a binding agent. These carriers may be useful for providing improved binding within the mixture of step (a), and the final mixture of the present invention.
- the carrier is in a solid form.
- the carrier may be added with the granulating fluid as described hereinafter.
- Example carriers useful in combination with active ingredients for pharmaceutical products include those selected from the group consisting of sugar, sugar alcohols, and mixtures thereof.
- Nonlimiting examples of sugars useful herein include lactose, glucose, maltodexthns, and sucrose.
- Sugar alcohols useful herein include sorbitol, xylitol, mannitol and maltitol.
- a preferred carrier of the present invention is selected from the group consisting of sucrose, mannitol, and mixtures thereof.
- a more preferred carrier is sucrose, which is generally used for antacid products.
- the carrier is present in the final mixture resulting from the method at an effective level, preferably at a level of from about 5% to about 80%, more preferably from about 35% to about 70%, more preferably still from about 40% to about 60% by weight of the mixture of the active ingredient and the carrier.
- Granulating fluid means a fluid which is suitable for making granules, wherein the granulating fluid is applied onto a mixture of the active ingredient and the carrier at step (a), then removed during a drying step to form granules.
- the hardness of the granule is caused by using excessive levels of granulating fluids and/or excessive levels of binding agent and/or over mixing (e.g., for an extended period of time) of the components, and/or slow evaporation of any excess granulating fluid from the final products. If the granulating fluid is allowed to evaporate during storage, the granules and/or the resulting tablets may become undesirably hard.
- Suitable granulating fluids useful herein include water, a mixture of water and ethyl alcohol, and isopropyl alcohol; more preferably water.
- the total amount of the granulating fluid added at step (a) is selected depending upon the wetting capacity of the mixture of the active ingredient and the carrier.
- the viscosity and binding capability of binding agents which may be added if needed, may also affect the total amount of the granulating fluid to be used.
- the amount of granulating fluid added to the active ingredient and the carrier is from about 2% to about 5.5% by weight of the active ingredient and the carrier.
- the total amount of the granulating fluid used in the present invention is from about 20% to about 80 % less than the granulating fluid used in conventional wet granulating methods. Consequently, the method can reduce drying time for making granules.
- the granulating fluid can further comprise other ingredients.
- additional ingredients are neither heat sensitive nor moisture sensitive.
- These ingredients can be either solid or liquid in form.
- Example ingredients include sorbitol and xylitol.
- the granulating fluid may also comprise a binding agent.
- a binding agent is particularly useful when a carrier, such as mannitol, may have a limited ability to bind the components of step (a) and/or the final resulting granules of the present method.
- the levels and types of binding agent are selected depending upon the character of the carriers, compatibility with other components, and desired characteristic of the final product.
- binding agents examples include sugar, sugar alcohols, starches such as starch paste and pregelatinized starch, poiyvinylpyrrolidone, cellulose derivatives, gelatin, gums, and mixture thereof.
- Preferred binding agents include sucrose, glucose, and mixtures thereof.
- the binding agent and the carrier may be made of the same material (e.g., a sugar carrier, and a granulating fluid comprising water and sugar as the binding agent).
- the binding agent and the carrier may be altogether different.
- mannitol may be used as a carrier.
- sugar may be used as a binding agent.
- their use as a carrier may negate the need to add a binding agent to the granulating fluid (e.g., granulating fluid may merely be water).
- the mixture of step (a) comprises an effective amount of the binding agents, preferably from about 0.1% to about 10% by weight, more preferably from about 0.2% to about 5%, more preferably still from about 0.5% to about 3%.
- the granulating fluid may further comprise a coloring agent.
- a coloring agent is added with the granulating fluid to facilitate a uniform distribution and mixing.
- the coloring agent is present at an effective level, preferably from about 10ppm to about 500ppm, more preferably from about 20ppm to about 250ppm by weight.
- step (b) comprises heating the mixture of step (a) in an air-tight container.
- Air-tight container refers to a container having an airproof condition (i.e., completely sealed without any leaks) during the heating step, to facilitate or favor the process of making granules
- the temperature and time period used for heating the mixture of step (a) is selected depending upon the desired characteristics of the resulting mixture (such as crystal structure and chemical property) so long as the temperature is distributed uniformly without overheating.
- the higher the temperature the shorter the time required for heating or drying the mixture of ingredients. Higher temperatures however, may cause melting, browning, undesirable chemical reaction between ingredients, and/or degradation of the ingredients or the resulting mixture. A higher temperature may even change the crystal structure of the ingredients in the resulting mixture. A higher temperature may also result in a non-uniform distribution of heat. A lower temperature requiring increased time at the heating step may cause similar interactions.
- the temperature for heating the mixture of step (a) is from about 50°C to about 100°C.
- the mixture of step (a) is heated from about 5 minutes to about 180 minutes. More preferably the mixture of step (a) is heated at, at least about 50°C for about 55 to about 135 minutes; more preferably at least about 70°C for about 20 to about 45 minutes; more preferably still at least about 80°C for about 5 to about 20 minutes in an air-tight container.
- the method further comprises drying the mixture of step (b).
- the resulting mixture of the present invention hereinafter called a "resulting granule,” is in the form of a granule comprising no more than about 1.5% by weight of the granulating fluid.
- the resulting granules have an average particle size of from about 150 microns to about 850 microns.
- the resulting granules can comprise less than about 10% particles which are above about 1200 microns or below about 50 microns.
- the resulting granules of the present invention can provide excellent properties such as improved dissolving and/or disintegrating and softness in the mouth when contacted with water or saliva.
- the granules made by the method of the present invention are bound by the combination of absorbed layer bonding and liquid bridge bonding mechanisms.
- the granules made by the method may further provide a good free flowing benefit and thereby easily processed.
- any conventional drying equipment is acceptable.
- Useful equipment includes for example, fluidized bed drier, vacuum drier, and the like.
- the temperature and time period used for drying the mixture of step (b) is selected depending upon the characteristics of the active ingredients, carriers, and the resulting granules.
- Preferably granules to be used for pharmaceuticals are dried at a temperature of from about 60°C to about 80 O C.
- the dried granules are, then passed through sieves #14 to have a desirable granule size.
- the sieves used herein are corresponded to those proposed as an international standard (ISO; International Standardization Organization).
- ISO International Standardization Organization
- a particle that passes through sieves #14 s e.g., U.S. Series Alternate Sieve Designation with 1400 micron opening
- the method for making granules of the present invention may be useful in a variety of industrial areas such as pharmaceutical, food and beverage, detergent, fertilizer, pesticide, and cosmetic areas, wherein a conventional wet granulation method has previously been useful.
- Example products made from the resulting granules of the present invention include tablet or granules (e.g., powder) for hot or cold drink mixes; pharmaceuticals; salt, animal feed, seasoning preparations; cleansing powders; detergents; fertilizer; pesticides; and cosmetics.
- the granules made by the method can be formulated into tablets, filled in capsules, or packed in sachets.
- the resulting granules of the present invention are used to make a pharmaceutical tablet composition.
- the pharmaceutical tablet composition made by the granules may further comprise from about 3% to about 30%, by weight of the tablet, of one or more other ingredients such as tableting aids, flavors, sweetening agents, and ingredients used in conventional pharmaceutical tablets.
- Tabletting aids refers to an ingredient that is added to the granules in small quantities to provide flowability to granules, to reduce friction, and/or to ease removal of the tablets from the tableting machine.
- the tableting aids useful herein include, for example, magnesium stearate, stearic acid, aerosil, talc, and mixtures thereof. Excess amount of other ingredients other than those added during making granules prepared as mentioned may not be distributed uniformly.
- the other ingredients are in a solid form to facilitate operating flowability and product stability.
- ingredients for tableting useful herein include, for example, diluents such as glucose, mannitol and direct compressible sugar; flavoring agents; sweetening agents; coloring agents; stabilizing agents such as agar, pectin, gums and starches; antioxidants such as ascorbic acid and BHA; cooling agents such as TK-10, WS-3 and WS-23; preservatives such as potassium sorbate and Sodium benzoate, and the like, referred to in U.S. Patent number 5,244,670, issued September 14, 1993 to Upson et. al; as well as other non-toxic compatible substances used in pharmaceutical formulation.
- the resulting tablets dissolve and/or disintegrate smoothly when contacted with water or saliva and produce little to no gritty sensation in the user's mouth.
- Examples I - V For Examples I through V, the sugar and CaC ⁇ 3 are mixed in a planetary mixer bowl (Rama Pharma, India). Water containing a dye is sprayed onto the mixture in the planetary mixer bowl during blending. The mixture is blended about 5 minutes at 60rpm. After the mixing is completed, the planetary mixer bowl is closed. The planetary mixer bowl is then heated to a temperature of at least about 80°C for about 20 minutes to agglomerate the mixture. The resulting agglomerates are dried at about 60°C in a tray drier to reduce the granulating fluids to levels below about 1.5% by weight of the resulting granules. The dried agglomerates are passed through #14 sieves. The resulting granules provide a soft mouth feel with minimal to no grittiness.
- the granules are mixed with glucose and blended for about 4 minutes. Flavor is then added and blended for about 4 more minutes. Magnesium stearate and Talc (in 1 :1 ratio) is added, the ingredients are mixed for another 2 minutes. The mixture is fed into a tableting machine to be compressed into tablets.
- a 20% sugar solution is prepared. Mannitol and CaC ⁇ 3 are mixed in a planetary mixer bowl (Rama Pharma, India). The 20% sugar solution is sprayed onto the mixture in the bowl during blending. The mixture is blended for about 5 minutes at 60rpm. After the mixing is completed, the planetary mixer bowl is closed. The planetary mixer bowl is then heated to a temperature of at least about 80°C for about 20 minutes to agglomerate the mixture. The resulting agglomerates are dried at about 60°C in a tray drier to reduce the granulating fluids to levels below about 1.5% by weight of the resulting granules. The dried agglomerates are passed through #14 sieves.
- the resulting granules are mixed with a direct compressible sugar and blended for about 4 minutes. Flavor is then added, the mixture is blended for about 4 more minutes. Magnesium stearate and Talc (in a 1 :1 ratio) is added, followed by an additional 2 minutes of mixing. The resulting mixture is fed into a tableting machine to be compressed into tablets.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1997/002830 WO1998036737A1 (fr) | 1997-02-25 | 1997-02-25 | Procede de granulation par voie humide |
AU19707/97A AU1970797A (en) | 1997-02-25 | 1997-02-25 | Wet granulating method |
JP10512609A JPH11506473A (ja) | 1997-02-25 | 1997-02-25 | 湿式粒状化方法 |
IDP980300A ID19965A (id) | 1997-02-25 | 1998-02-27 | Metoda pembutiran basah |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1997/002830 WO1998036737A1 (fr) | 1997-02-25 | 1997-02-25 | Procede de granulation par voie humide |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998036737A1 true WO1998036737A1 (fr) | 1998-08-27 |
Family
ID=22260415
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/002830 WO1998036737A1 (fr) | 1997-02-25 | 1997-02-25 | Procede de granulation par voie humide |
Country Status (4)
Country | Link |
---|---|
JP (1) | JPH11506473A (fr) |
AU (1) | AU1970797A (fr) |
ID (1) | ID19965A (fr) |
WO (1) | WO1998036737A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003092658A1 (fr) * | 2002-04-29 | 2003-11-13 | Egis Gyógyszergyár Rt | Procede de preparation de comprimes a partir de substances, actives sur le plan pharmaceutique, ne possedant pas de proprietes favorables a la mise en comprime, avec un liquide de granulation contenant de la cellulose microcristalline |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3315800A1 (de) * | 1983-04-30 | 1984-10-31 | Merck Patent Gmbh, 6100 Darmstadt | Verfahren zur herstellung eines granulats |
EP0330284A2 (fr) * | 1988-02-25 | 1989-08-30 | Yamanouchi Europe B.V. | Procédé de préparation d'un granulé pharmaceutique |
EP0368682A1 (fr) * | 1988-11-11 | 1990-05-16 | Euroceltique S.A. | Composition pharmaceutique à base d'une résine d'échange ionique |
JPH05105636A (ja) * | 1991-10-14 | 1993-04-27 | Lion Corp | 制酸剤組成物 |
WO1996017611A1 (fr) * | 1994-12-07 | 1996-06-13 | The Wellcome Foundation Limited | Composition pharmaceutique contenant de la lamotrigine |
-
1997
- 1997-02-25 WO PCT/US1997/002830 patent/WO1998036737A1/fr active Application Filing
- 1997-02-25 JP JP10512609A patent/JPH11506473A/ja active Pending
- 1997-02-25 AU AU19707/97A patent/AU1970797A/en not_active Abandoned
-
1998
- 1998-02-27 ID IDP980300A patent/ID19965A/id unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3315800A1 (de) * | 1983-04-30 | 1984-10-31 | Merck Patent Gmbh, 6100 Darmstadt | Verfahren zur herstellung eines granulats |
EP0330284A2 (fr) * | 1988-02-25 | 1989-08-30 | Yamanouchi Europe B.V. | Procédé de préparation d'un granulé pharmaceutique |
EP0368682A1 (fr) * | 1988-11-11 | 1990-05-16 | Euroceltique S.A. | Composition pharmaceutique à base d'une résine d'échange ionique |
JPH05105636A (ja) * | 1991-10-14 | 1993-04-27 | Lion Corp | 制酸剤組成物 |
WO1996017611A1 (fr) * | 1994-12-07 | 1996-06-13 | The Wellcome Foundation Limited | Composition pharmaceutique contenant de la lamotrigine |
Non-Patent Citations (1)
Title |
---|
DATABASE WPI Section Ch Week 9321, Derwent World Patents Index; Class B06, AN 93-172631, XP002045396 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003092658A1 (fr) * | 2002-04-29 | 2003-11-13 | Egis Gyógyszergyár Rt | Procede de preparation de comprimes a partir de substances, actives sur le plan pharmaceutique, ne possedant pas de proprietes favorables a la mise en comprime, avec un liquide de granulation contenant de la cellulose microcristalline |
Also Published As
Publication number | Publication date |
---|---|
JPH11506473A (ja) | 1999-06-08 |
ID19965A (id) | 1998-08-27 |
AU1970797A (en) | 1998-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3627583A (en) | Direct compression vehicles | |
US4747881A (en) | Ingestible aggregate and delivery system prepared therefrom | |
EP0587744B1 (fr) | Composition a macher liberant un medicament | |
CA1272134A (fr) | Systeme d'administration de medicaments | |
JP4213867B2 (ja) | 経口用カルシウム組成物の調製方法 | |
US4790991A (en) | Ingestible aggregate and delivery system prepared therefrom | |
US4851392A (en) | Ingestible aggregate and delivery system prepared therefrom | |
US4818539A (en) | Ingestible aggregate and delivery system prepared therefrom | |
US3639169A (en) | Direct compression vehicles and method therefor | |
US4806358A (en) | Therapeutic compositions | |
US4704269A (en) | Effervescent antacid and analgesic compositions | |
KR101438071B1 (ko) | 약학 조성물 | |
JP2546068B2 (ja) | L−カルニチン含有製剤 | |
EP1538921B1 (fr) | Formulation de chewing-gum et procede de fabrication | |
EP0275834A1 (fr) | Procédé en continu pour la préparation d'un comprimé à mâcher | |
US4843098A (en) | Ingestible aggregate and delivery system prepared therefrom | |
EP0890358A1 (fr) | Comprimé à macher soluble, dragéifié, contenant des gommes | |
US5073377A (en) | Method of preparing oral dosage forms with a granulating composition | |
JPS6061517A (ja) | 圧縮成形錠剤 | |
JP2882895B2 (ja) | 改善された口触りを有する低カロリー圧縮錠剤 | |
DE19859231A1 (de) | Schäumende Antacida-Suspensionstabletten | |
DE69012932T2 (de) | Zubereitung für schäumendes Präparat. | |
US3821414A (en) | Direct compression vehicle | |
US5618527A (en) | Calcium polycarbophil sprinkle | |
JP3230814B2 (ja) | 炭酸マグネシウムおよびオイルタブレット形成助剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 512609 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |